Jin-Long Chen

MedImmune, NGM Biopharmaceuticals in exclusive agreement to discover, develop and commercialise therapies for diabetes and obesity

25-6-2013 — /europawire.eu/ — AstraZeneca today announced that MedImmune, its global biologics research and development arm, and NGM Biopharmaceuticals, Inc. have…

11 years ago